The Latest Breaking News from Amgen

The Dow Jones was up on Election Day. A number of 'Republican stocks' gained but the Donald Trump SPAC fell. Bitcoin fell on an FTX buyout.

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Reuters

Friday's jobs report will reinforce or ease Fed chief Powell's hawkish comments. Apple, Google were market rally drags.

Amgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter beat and strong Evenity sales.

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Upgrades

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Putting some simple math to calculate the 200-day moving average of a stock can help investors make better decisions.

Amgen sees its Relative Strength Rating reach the elite 90-plus level.